An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

British Journal of Haematology

Volumn 161, Issue 2, 2013, Pages 282-286

  Rösner, Thies ^a   Derer, Stefanie ^a   Kellner, Christian ^a   Dechant, Michael ^a   Lohse, Stefan ^a   Vidarsson, Gestur ^b   Peipp, Matthias ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Chronic lymphocytic leukaemia; Complement dependent cytotoxicity; IgG3; Rituximab

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; DECAY ACCELERATING FACTOR; ECULIZUMAB; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MEMBRANE COFACTOR PROTEIN; OFATUMUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BIOCHEMISTRY; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; IMMUNOFLUORESCENCE; LETTER; LEUKEMIA CELL; LYMPHOMA CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 84875805834     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12209     Document Type: Letter

References (10)

1. Bindon, C.I., Hale, G., Brüggemann, M. & Waldmann, H. (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. Journal of Experimental Medicine, 168, 127-142.
2. Boross, P. & Leusen, J.H. (2012) Boosting antibody therapy with complement. Blood, 119, 5945-5947.
3. Brekke, O.H., Michaelsen, T.E. & Sandlie, I. (1995) The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunology Today, 16, 85-90.
4. Dechant, M., Vidarsson, G., Stockmeyer, B., Repp, R., Glennie, M.J., Gramatzki, M., van De Winkel, J.G. & Valerius, T. (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood, 100, 4574-4580.
5. Glennie, M.J., French, R.R., Cragg, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 44, 3823-3837.
6. Grillo-Lopez, A.J., White, C.A., Varns, C., Shen, D., Wei, A., McClure, A. & Dallaire, B.K. (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Seminars in Oncology, 26, 66-73.
7. van Meerten, T., van Rijn, R.S., Hol, S., Hagenbeek, A. & Ebeling, S.B. (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research, 12, 4027-4035.
8. Michaelsen, T.E., Garred, P. & Aase, A. (1991) Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. European Journal of Immunology, 21, 11-16.
9. Stapleton, N.M., Andersen, J.T., Stemerding, A.M., Bjarnarson, S.P., Verheul, R.C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., Jonsdottir, I., van der Schoot, C.E. & Vidarsson, G. (2011) Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Communications, 2, 599.
10. Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G.J. & Glennie, M.J. (2004) Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against Non-Hodgkin's lymphoma. Blood, 104, 1793-1800.